Guggenheim raised the firm’s price target on Eli Lilly (LLY) to $1,163 from $1,036 and keeps a Buy rating on the shares after updating the firm’s Lilly and Novo Nordisk (NVO) models to reflect prescription trends and GLP-1 pricing updates and announcements. While noting that Lilly has “delivered another impressive year of stock performance in 2025,” the firm “simply cannot argue with the company’s superior overall execution capitalizing fully on the Pharma mega cycle of our lifetime,” the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- BMO Capital Markets Reiterates Buy Rating on Eli Lilly Stock (LLY)
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports
- Eli Lilly & Co: Strategic Pricing and Pipeline Success Drive Promising Growth Prospects
- Vaccine committee considers changes to childhood schedule, NY Times reports